Antibodies or ligands against human ABCA1 combined with radionuclides and uses thereof
By conjugating human ABCA1 antibodies and radionuclides, the specificity and safety of radioactive drugs in the prior art are solved, and efficient targeted treatment of gliomas is achieved, and the treatment is improved Efficiency and reduce side effects.
Patent Information
- Application Number
- CN202011263638.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-12
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing radioactive drugs lack high specific targeting of the lesion site when treating gliomas, and are easily enriched in normal organs, resulting in organ damage, and the blood circulation time does not match the half-life, which limits its clinical application.
Develop a radionuclide drug containing an antibody or ligand against human ABCA1, conjugated to the radionuclide through an antibody or antigen binding fragment for targeting the treatment of gliomas, including antibody-drug conjugates and fusion proteins, It is preferred to use α-ray nuclides 211At, 225Ac, etc. in combination with pharmaceutically acceptable carriers and active ingredients.
It improves the specific targeting of drugs to gliomas, reduces damage to normal organs, prolongs therapeutic activity in the body, enhances treatment efficiency and reduces toxic side effects.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biopharmaceuticals, and specifically relates to antibodies or ligands against human ABCA1 combined with radionuclides and uses thereof, especially uses thereof in targeted treatment of glioma (LGG) or glioblastoma multiforme (GBM). Background Art
[0002] Gliomas are one of the most common and serious types of nervous system tumors. Gliomas usually have a very grim prognosis and are highly life-threatening diseases.
[0003] Gliomas are usually classified by cell type, grade, and location, and are most often classified according to specific types of cells because glioma cells share many common histological features with these specific types of cells. It should be noted that the specific types of cells mentioned above are not necessarily the primary cell types of gliomas. At present, the main types of gliomas and the corresponding specific types of cells are as follows: ependymoma (ependymal cells), astrocytoma (astrocytes), oligodendroglioma (oligodendrocytes), brainstem glioma (brainstem), optic nerve glioma (cells in or around the optic nerve) and mixed glioma (cells from different types of glial cells). Of course, they can also be divided into optic nerve gliomas (which can cause visual impairment or vision loss) and spinal cord gliomas according to their corresponding specific cell types.
[0004] On the other hand, according to the WHO, gliomas are also further graded. Grade I is the lowest grade with the best prognosis and the earliest stage of glioma development, and grade I gliomas are generally considered benign. Grade II is the grade just above the lowest grade, in which the glioma is highly differentiated rather than undifferentiated cancer. Grades III and IV are undifferentiated or anaplastic cancers and are obviously malignant. The prognosis of grades III and IV is very poor. However, it should be noted that grades I and II have a better prognosis, but these grades of gliomas will change over time, such as increasing difficulty in treatment and a tendency to increase in grade.
[0005] Gliomas are classified based on their location, specifically whether they are above or below the dural septum. Supraseptal gliomas are more common in adults, while subseptal gliomas are more common in younger people.
[0006] The symptoms of glioma patients vary depending on the size of the tumor, how fast it grows, where it occurs, etc. Usually, glioma patients mainly experience convulsions, headaches or migraines, abnormal neurological function (such as memory problems and speech problems), and poor mental state.
[0007] Treatment of gliomas usually involves surgical resection followed by radiation therapy and chemotherapy. Glioblastomas are more common than other major types of central nervous system tumors. They can be treated with a combination of temozolomide and radiation therapy followed by adjuvant therapy, but the median survival is not long.
[0008] The exact cause of glioma is still unclear. Current studies have shown that the occurrence of glioma is related to gene mutations, such as DNA repair genes ERGC1, ERGC2, XRCC1, isocitrate dehydrogenase genes IDH1 and IDH2, p53, PTEN, etc.
[0009] In fact, gliomas are rarely curable, and patients with high-grade gliomas generally have a worse prognosis. Therefore, there is a great need to improve the treatment of gliomas.
[0010] ATP-binding Gassette transporter A1 (ABCA1) is an ATP-dependent transporter that mediates the efflux of cholesterol and phospholipids to extracellular lipid-deficient HDL particles. ABCA1 acts as a key regulator of lipid efflux from cells to apolipoproteins and is therefore involved in reducing the risk of atherosclerosis. Further, ABCA1 is a key molecule that affects HDL levels in plasma. In the liver and small intestine, human ABCA1 produces most of the circulating HDL.
[0011] Radioactive isotope drugs are an important part of nuclear medicine and are widely used in the diagnosis and treatment of cancer, myocardial imaging and diagnosis of heart diseases, as well as the status monitoring of neurodegenerative diseases. Radioactive drugs refer to a special class of drugs containing radioactive isotopes for medical diagnosis and treatment. Compounds or biological agents labeled with radioactive isotopes used for medical diagnosis or treatment in the body. Radioactive drugs are divided into diagnostic radioactive drugs and therapeutic radioactive drugs according to their uses. Targeted radioactive isotope drugs using internal irradiation have good therapeutic effects and low side effects, especially for diffuse cancer and micro-metastatic cancer. They are a perfect complement to ion beam tumor therapy and have become a new trend in the development of radioactive tumor therapeutic drugs in Europe and the United States. Although isotope imaging and treatment have obvious advantages and application prospects, they also have some problems, such as the lack of high-specific targeting of lesions, organ damage caused by enrichment in normal organs, and mismatch between blood circulation time and half-life, which hinder their further clinical application. There is an urgent need to develop targeted diagnostic and therapeutic isotopes to improve their therapeutic efficiency and reduce toxic side effects. Summary of the invention
[0012] In order to better cure glioma or provide another feasible option for treating glioma and improve the prognosis or quality of life of patients, the inventors of the present invention have found through extensive and persistent screening that nuclides can be conjugated to antibodies or ligands against human ABCA1 to treat glioma.
[0013] Therefore, the present invention provides an anti-ABCA1 antibody and an antigen-binding fragment thereof. Further, the antigen-binding fragment of the present invention can be selected from the following group: camel Ig, Ig NAR, Fab fragment, Fab' fragment, F(ab)' 2 Fragment, F(ab)' 3 Fragment, Fv, scFv, Bi-scFv, (scFv) 2 , mini antibodies, double-chain antibodies, three-chain antibodies, four-chain antibodies, disulfide-bond-stabilized Fv proteins, single-domain antibodies (sdAb, nanoantibodies), bispecific antibodies or trispecific antibodies, etc.
[0014] Furthermore, the present invention also provides a fusion protein comprising the above-mentioned antibody or antigen-binding fragment.
[0015] Exemplarily, the fusion protein described in the present invention may further comprise a tag sequence (eg, Poly-His, Hemagglutinin, c-Myc, GST, Flag-tag, etc.) or an IgG1-Fc protein sequence.
[0016] The present invention also provides an antibody-drug conjugate, which comprises the antibody or antigen-binding fragment described in the present invention.
[0017] Exemplarily, in the antibody-drug conjugate of the present invention, the drug is selected from the following: radionuclides (preferably α-ray nuclides 211At, 225Ac, 223Ra), 32 P. 35 S, fluorescent dyes, electron-dense reagents, enzymes, biotin, streptavidin, digoxigenin, haptens, immunogenic proteins, nucleic acid molecules having a sequence complementary to a target, or any combination of the foregoing; or immunomodulatory compounds, anticancer agents, antiviral agents, antibacterial agents, antifungal agents, and antiparasitic agents, or any combination of the foregoing.
[0018] One aspect of the present invention relates to a drug for treating glioma, which contains the drug conjugate of the present invention. Optionally, the drug of the present invention further contains a pharmaceutically acceptable carrier.
[0019] Preferably, the drug for treating glioma of the present invention further contains other active ingredients for treating glioma.
[0020] The second aspect of the present invention provides the use of the antibody of the present invention or the drug conjugate of the present invention in the preparation of a drug for treating glioma. Optionally, the drug for treating glioma also contains a pharmaceutically acceptable carrier. Preferably, the drug for treating glioma also contains other active ingredients for treating glioma.
[0021] A third aspect of the present invention provides a method for treating glioma in a subject, comprising administering to the subject an effective amount of the drug conjugate of the present invention.
[0022] Exemplarily, the other active ingredient described in the present invention may be temozolomide.
[0023] The subject described in the present invention is preferably a mammal, more preferably a human.
[0024] Those skilled in the art may make any modification to the drug conjugate of the present invention, provided that the modification does not negatively affect its activity. For example, multiple radionuclides may be conjugated to the drug conjugate to improve its therapeutic activity in vivo; or it may be connected to a known penetrating peptide to promote transdermal absorption of the compound of the present invention or cross the blood-brain barrier, etc. In short, those skilled in the art may make various modifications to the drug conjugate of the present invention to improve delivery efficiency or for other purposes while maintaining its activity. Such modifications are also within the scope of the present invention.
[0025] In the present invention, in addition to the active ingredient, the method, use and product of the present invention may also contain a suitable pharmaceutically acceptable carrier, including excipients and adjuvants that facilitate processing of the active ingredient into a preparation (eg, a preparation suitable for injection or infusion).
[0026] Formulations suitable for injection or infusion may include aqueous and non-aqueous sterile injection solutions and aqueous and non-aqueous sterile suspensions, the sterile injection solution may optionally contain antioxidants, buffers, bacteriostats and solutes that can make the formulation isotonic with the blood of the intended recipient, and the sterile suspension may include suspending agents and thickening agents. The formulation may be present in unit dose or multi-dose containers, such as sealed ampoules, and may be stored in a freeze-dried (lyophilized) condition, requiring only the addition of a sterile liquid carrier, such as water for injection, before immediate use.
[0027] The various cytokine active ingredients of the present invention can be optionally combined with solid excipients, and the resulting mixture is optionally ground, and if necessary, after adding suitable auxiliary agents, the mixture of particles is processed to obtain the desired dosage form. Suitable excipients are particularly fillers such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose or starch preparations, gelatin, tragacanth, methylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and / or polyvinylpyrrolidone (PVP). If necessary, disintegrants such as cross-linked polyvinylpyrrolidone, agar or alginic acid or its salts such as sodium alginate can be added.
[0028] In the present invention, the amount of the drug conjugate of the present invention administered may be any amount that can treat glioma or inhibit the proliferation of glioma cells in a subject.
[0029] In the present invention, determination of the effective amount and appropriate unit dosage for administration is well within the capability of those skilled in the art, especially in light of the disclosure provided herein.
[0030] According to the present invention, the pharmaceutical drug of the present invention can be administered to the subject at any effective dose. Preferably, the drug of the present invention can be administered in multiple doses, such as from about 5 to about 15 doses, more preferably from about 6-10 doses, and most preferably about 8 doses. In a particularly preferred embodiment, during administration, the drug of the present invention is administered to the subject at a frequency of about once every two weeks, such as by injection, infusion or oral administration. In a particularly preferred embodiment, administration is administered by intravenous injection.
[0031] It will be appreciated that the medicaments of the present invention may be formulated in any suitable manner for administration by any suitable route.
[0032] The dosage unit of the drug of the present invention is based on the routine administration to the subject. For example, the dosage unit can be determined based on the administration frequency of once a day, once a week, once a month, etc. The dosage unit can also be determined based on twice / week, three times / week, etc.
[0033] As used herein, "comprising" is synonymous with "including", "containing" or "characterized by", and is inclusive or open-ended, and does not exclude additional unstated elements or method steps. The term "comprising" in any statement herein, particularly when describing the method, use or product of the present invention, should be understood to include those products, methods and uses consisting essentially of and consisting of the components or elements or steps. The present invention exemplarily described herein can be practiced appropriately in the absence of any one or more elements, one or more limitations not specifically disclosed herein.
[0034] The drug of the present invention may include instructions related to the pharmaceutical product, and the instructions may contain the following contents: indications (such as glioma), dosage (such as exemplified above), possible side effects, etc.
[0035] The terms and expressions that have been adopted herein are used as descriptive rather than limiting terms, and in the use of such terms and expressions, it is not intended to exclude any equivalents of the features shown and described or parts thereof, but it should be recognized that various modifications are possible within the scope of the invention claimed. Therefore, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modifications and variations of the concepts disclosed herein may be adopted by those skilled in the art, and such modifications and variations are considered to be within the scope of the invention as defined by the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 It is intravenous 68 Transverse PET-CT image 30 minutes after Ga-DOTA-NCS-ABCA1 probe. The red circle shows the tumor site.
[0037] Figure 2 It is intravenous 68 The ratio of the radioactive probe accumulation in HepG2 tumor and tumor-bearing mouse muscle after 30min, 60min, and 90min of Ga-DOTA-NCS-ABCA1 (T / M).
[0038] Figure 3 It is intravenous 68 The ratio of the radioactive probe accumulation in MDA-MD-231 tumor and in the muscle of tumor-bearing mice after 30min, 60min, and 90min of Ga-DOTA-NCS-ABCA1 (T / M).
[0039] In order to more clearly illustrate the present invention, it is now described in detail in conjunction with the following examples, but these examples are merely exemplary descriptions of the present invention and cannot be interpreted as limiting the present application.
[0040] ATP-binding cassette transporter A1 (ABCA1) is an important member of the ATP-binding cassette transporter superfamily. It plays an extremely important regulatory role in reverse cholesterol transport, cholesterol metabolism, and high-density lipoprotein (HDL) metabolism. ABCA1 gene mutations can induce Tangier disease and familial HDL deficiency. Recent studies have shown that ABCA1-mediated cholesterol efflux function has anti-tumor activity, and ABCA1 is expected to become a new target for tumor treatment.
[0041] Liver cancer is a malignant tumor of the liver, which can be divided into two categories: primary and secondary. Primary malignant liver tumors originate from the epithelial or mesenchymal tissue of the liver. The former is called primary liver cancer, which is a highly prevalent and extremely harmful malignant tumor in my country; the latter is called sarcoma, which is relatively rare compared with primary liver cancer. Secondary or metastatic liver cancer refers to malignant tumors originating from multiple organs throughout the body that invade the liver. It is generally common in liver metastases from malignant tumors of organs such as the stomach, bile duct, pancreas, colorectum, ovary, uterus, lung, and breast.
[0042] Triple-negative breast cancer clinically presents as an aggressive course of disease with a higher risk of distant metastasis, a higher chance of visceral metastasis than bone metastasis, and a higher chance of brain metastasis. The risk of distant metastasis of triple-negative breast cancer peaks at 3 years and may decline thereafter. The median tumor size of triple-negative breast cancer is 2 cm, and 50% have lymph node metastasis. The histological grade of this type of breast cancer is mostly grade 3, and the proportion of cell proliferation is high.
[0043] 1 Reasons for choosing a test system
[0044] According to the Technical Guidelines for Nonclinical Pharmacokinetic Studies of Drugs, nude mice are mice with congenital thymus defects. They are hairless and lack normal thymus. Their characteristics include T cell defects, so they can accept foreign transplanted cells and are less likely to have immune rejection, making them suitable for xenotransplantation.
[0045] Marking and identification of animals
[0046] During the quarantine adaptation period, the animals are marked with their own animal ID numbers, and the animal numbers are used after grouping. During the experiment, each animal has a unique animal number, and a cage card is attached to the animal cage. The cage card contains information such as the subject number, animal number, animal ID number, group, and gender.
[0047] Quarantine and adaptive feeding
[0048] All animals were quarantined and adapted for at least 7 days under the following conditions: temperature 20℃~27℃, humidity 45%~75%, and 12-hour light-dark cycle.
[0049] Cage
[0050] The animals were housed in an IVC with an independent ventilation system, with no more than 5 animals per cage.
[0051] Test animal feed
[0052] Feed type: mouse maintenance feed
[0053] Manufacturer: Jiangsu Synergy Pharmaceutical Bioengineering Co., Ltd.
[0054] Production license number: Sushi Certificate (2014) 01008, SCXK (Beijing) 2014-0010
[0055] Feed batch number: 20180530; 18068221
[0056] Validity period: 20190529
[0057] Storage conditions: low temperature, dry and hygienic
[0058] Feeding method: Free diet
[0059] Feed testing: Each batch of feed has a quality certificate provided by the manufacturer; a third-party qualified professional testing unit conducts routine nutritional component, chemical pollutant and microbial testing on the feed once a year.
[0060] Drinking water for experimental animals
[0061] The mice were fed with sterilized purified drinking water through a water bottle in the cage, which was available ad libitum.
[0062] Radiolabeling
[0063] NOTA-ABCA1 preparation
[0064] Dissolve 1 mg NOTA-NCS in 1 mL HO. 2 O, take 50uL (50ug, 62nmol) and add it to the reconstituted ABCA1 antibody (1mg, 74nmol, Anti-ABCA1 antibody [AB.H10], purchased from abcam, mouse monoclonal antibody [AB.H10] toABCA1, immunogen: Recombinant fragment corresponding to Human ABCA1 aa 1800-2260.Database link: 095477), the ratio of antibody to NOTA-NCS is 1:1, and at the same time, add 20uL of 0.1M NaHCO3 solution, protect from light, and shake at 25°C for 0.5h.
[0065] 68 Preparation of Ga ions
[0066] The germanium gallium generator was eluted with 5 mL of 0.1 M HCl, and the hydrochloric acid eluate was collected in sections. The part with the highest activity in the middle section (7 mCi, 0.5 mL) was taken and added with 500 uL of sodium acetate buffer (0.1 mol / L, PH=4.3).
[0067] 68 Preparation of Ga-DOTA-NCS-ABCA1
[0068] Take the prepared DOTA-NCS-ABCA1 solution and add 68 Ga 3+ The mixture was reacted in sodium acetate buffer solution at 40°C for 30 min.
[0069] Separation and purification
[0070] Pre-activate the PD-10 desalting column, dilute the product and load 2.5 mL of sample. After the sample is emptied, fill it with buffer and start collecting samples. Connect 10 tubes for every 10 drops (about 0.35 mL). Test the radioactivity with an activity meter and take the tube with the highest activity in the front section for the experiment.
[0071] Radiochemical purity determination
[0072] TLC detection was performed using Xinhua No. 1 paper and sodium acetate buffer as the developing solvent.
[0073] Tumor model establishment
[0074] Cell culture
[0075] HepG2 and MDA-MD-231 cell lines were routinely cultured and expanded. Fresh culture medium was replaced one day before inoculation, the culture medium in the culture flask was discarded, PBS was washed twice, 1 mL of 0.25% trypsin containing EDTA was added for digestion, and the cells were observed to curl and round under a microscope. The cell culture flask was tapped to make the cells fall off, and then complete culture medium was added to terminate digestion. Centrifugation was performed at 800 rpm for 5 min. The cells were resuspended in serum-free culture medium and the cell concentration was adjusted to 1×10 7 Pieces / mL;
[0076] Cell seeding
[0077] Inoculate 0.1 mL of the solution in the right armpit of each nude mouse. 3 For formal experimental research.
[0078] Micro-PET / CT Scan
[0079] 1) Micro-PET / CT warm-up and daily calibration;
[0080] 2) Animals were weighed and nude mice were anesthetized with isoflurane;
[0081] 3) Static scanning: After the righting reflex of the animal disappears, the imaging agent is injected into the tail vein, about 60uci per animal, with a volume of 0.1mL. The animals are anesthetized and fixed to the scanning bed 30min, 60min and 90min after the injection. The PET static scan is performed for 10min, and a CT scan is performed.
[0082] Drug administration information and dosage design
[0083] Route and method of administration: Tail vein injection
[0084] Reason for choosing the route of administration: consistent with the intended clinical administration method
[0085] Dosing frequency and duration: Single dose
[0086] Dosing volume: 0.1mL
[0087] Image analysis
[0088] Micro-PET / CT scan data analysis, animal tumor and muscle uptake quantification, and tumor-to-muscle ratio determination were performed using Siemens' own software.
[0089] result:
[0090] The probe is rapidly cleared from the blood and excreted primarily through the kidneys. The probe accumulates significantly in both tumors ( Figure 1 ).right 68 The T / NT value of Ga-DOTA-NCS-ABCA1 probe imaging at 90 minutes after injection is shown in the figure below. In HepG2 cells, the T / NT value of tumor / muscle at 90 minutes was the largest, which was 2.27±0.18 ( Figure 2 In MDA-MD-231 cells, the T / NT value of tumor / muscle at 30 min was the largest, which was 3.36±0.30 ( Figure 3 ).
Claims
1. Use of an antibody-drug conjugate in the preparation of a preparation for diagnosing a tumor, wherein the antibody-drug conjugate comprises an antibody against human ABCA1, wherein the drug is 68 Ga, wherein the structure of the conjugate is: 68 Ga-DOTA-NCS-ABCA1, wherein the tumor is breast cancer or liver cancer; Said 68 The preparation method of Ga-DOTA-NCS-ABCA1 is: (1) Preparation of DOTA-NCS-ABCA1 Dissolve 1 mg of DOTA-NCS in 1 mL of H2O, take 50 μL and add it to the reconstituted ABCA1 antibody, with the ratio of antibody to DOTA-NCS being 1:1, and add 20 μL of 0.1 M NaHCO3 solution at the same time, protect from light, and shake at 25°C for 0.5 h to obtain DOTA-NCS-ABCA1; (2) 68 Preparation of Ga ions The germanium gallium generator was washed with 5 mL of 0.1 M HCl, and the hydrochloric acid eluate was collected in sections. The middle section with the highest activity (7 mCi) was taken, and 0.5 mL was added with 500 uL of 0.1 mol / L, pH = 4.3 sodium acetate buffer to obtain 68 Sodium acetate buffer solution of Ga3+; (3) 68 Preparation of Ga-DOTA-NCS-ABCA1 Take the DOTA-NCS-ABCA1 solution prepared in step (1) and add it to the 68 Ga3+ in sodium acetate buffer solution, react at 40℃ for 30min to obtain 68 Ga-DOTA-NCS-ABCA1.
Citation Information
Patent Citations
Novel radionuclide labelled somatostatin analogue molecular probe and application thereof
CN104491890A
